Robert Azelby - 03 Jun 2025 Form 4 Insider Report for ADC Therapeutics SA (ADCT)

Reporting relationship: Director
Issuer ticker: ADCT
Reported as of: 03 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2025, 17:10:51 UTC
Prior SEC filing: 24 Feb 2025
Next SEC filing: 17 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Lisa Kallebo, as Attorney-in-Fact for Robert Azelby

Key filing fact

Robert Azelby filed Form 4 for ADC Therapeutics SA (ADCT) on 05 Jun 2025.

Key facts

This page summarizes Robert Azelby's Form 4 filing for ADC Therapeutics SA (ADCT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jun 2025, 17:10.

Change

Previous filing in this sequence was filed on 24 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001656998 Primary reporting owner

Azelby Robert

Relationship: Director
Address: 430 MOUNTAIN AVENUE, SUITE 404, NEW PROVIDENCE
Signature: /s/ Lisa Kallebo, as Attorney-in-Fact for Robert Azelby
Signature date: 05 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADCT transaction

Common Shares

Award

Transaction value: $0
Shares: +40,000
Change %: +75%
Price: $0.000000
Shares after: 93,005
Date: 03 Jun 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.